Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2018 2
2019 4
2020 1
2021 1
2022 5
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA; RUBY Investigators. Mirza MR, et al. N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27. N Engl J Med. 2023. PMID: 36972026 Clinical Trial.
Systematic identification of anticancer drug targets reveals a nucleus-to-mitochondria ROS-sensing pathway.
Zhang J, Simpson CM, Berner J, Chong HB, Fang J, Ordulu Z, Weiss-Sadan T, Possemato AP, Harry S, Takahashi M, Yang TY, Richter M, Patel H, Smith AE, Carlin AD, Hubertus de Groot AF, Wolf K, Shi L, Wei TY, Dürr BR, Chen NJ, Vornbäumen T, Wichmann NO, Mahamdeh MS, Pooladanda V, Matoba Y, Kumar S, Kim E, Bouberhan S, Oliva E, Rueda BR, Soberman RJ, Bardeesy N, Liau BB, Lawrence M, Stokes MP, Beausoleil SA, Bar-Peled L. Zhang J, et al. Among authors: bouberhan s. Cell. 2023 May 25;186(11):2361-2379.e25. doi: 10.1016/j.cell.2023.04.026. Epub 2023 May 15. Cell. 2023. PMID: 37192619
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.
Konstantinopoulos PA, Lee EK, Xiong N, Krasner C, Campos S, Kolin DL, Liu JF, Horowitz N, Wright AA, Bouberhan S, Penson RT, Yeku O, Bowes B, Needham H, Hayes M, Sawyer H, Polak M, Shea M, Cheng SC, Castro C, Matulonis UA. Konstantinopoulos PA, et al. Among authors: bouberhan s. J Clin Oncol. 2023 Jan 20;41(3):599-608. doi: 10.1200/JCO.22.00628. Epub 2022 Sep 29. J Clin Oncol. 2023. PMID: 36174113 Clinical Trial.
Identification of chemotherapy targets reveals a nucleus-to-mitochondria ROS sensing pathway.
Zhang J, Simpson CM, Berner J, Chong HB, Fang J, Sahin ZO, Weiss-Sadan T, Possemato AP, Harry S, Takahashi M, Yang TY, Richter M, Patel H, Smith AE, Carlin AD, Hubertus de Groot AF, Wolf K, Shi L, Wei TY, Dürr BR, Chen NJ, Vornbäumen T, Wichmann NO, Pooladanda V, Matoba Y, Kumar S, Kim E, Bouberhan S, Olivia E, Rueda B, Bardeesy N, Liau B, Lawrence M, Stokes MP, Beausoleil SA, Bar-Peled L. Zhang J, et al. Among authors: bouberhan s. bioRxiv [Preprint]. 2023 Mar 11:2023.03.11.532189. doi: 10.1101/2023.03.11.532189. bioRxiv. 2023. PMID: 36945474 Free PMC article. Updated. Preprint.
Guideline-Discordant Care in Early-Stage Vulvar Cancer.
Bercow AS, Rauh-Hain JA, Melamed A, Mazina V, Growdon WB, Del Carmen MG, Goodman A, Bouberhan S, Bregar A, Eisenhauer EL, Molina G, Minami C. Bercow AS, et al. Among authors: bouberhan s. Obstet Gynecol. 2022 Dec 1;140(6):1031-1041. doi: 10.1097/AOG.0000000000004992. Epub 2022 Nov 2. Obstet Gynecol. 2022. PMID: 36357957
Financial toxicity in gynecologic oncology.
Bouberhan S, Shea M, Kennedy A, Erlinger A, Stack-Dunnbier H, Buss MK, Moss L, Nolan K, Awtrey C, Dalrymple JL, Garrett L, Liu FW, Hacker MR, Esselen KM. Bouberhan S, et al. Gynecol Oncol. 2019 Jul;154(1):8-12. doi: 10.1016/j.ygyno.2019.04.003. Epub 2019 Apr 30. Gynecol Oncol. 2019. PMID: 31053404 Free PMC article.
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.
Konstantinopoulos PA, Gockley AA, Xiong N, Krasner C, Horowitz N, Campos S, Wright AA, Liu JF, Shea M, Yeku O, Castro C, Polak M, Lee EK, Sawyer H, Bowes B, Moroney J, Cheng SC, Tayob N, Bouberhan S, Spriggs D, Penson RT, Fleming GF, Nucci MR, Matulonis UA. Konstantinopoulos PA, et al. Among authors: bouberhan s. JAMA Oncol. 2022 Sep 1;8(9):1317-1322. doi: 10.1001/jamaoncol.2022.2181. JAMA Oncol. 2022. PMID: 35900726 Free PMC article. Clinical Trial.
19 results